Before deciding the "societal value" of the new medicine, its performance in clinical trials, possible side effects, and accessibility must be closely examined.
Few manufacturers — such as Japan’s Eisai and the U.S.’ Biogen — have continued to develop a treatment. We hope the health ministry announces the approval...